IL157955A0 - Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp - Google Patents

Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp

Info

Publication number
IL157955A0
IL157955A0 IL15795502A IL15795502A IL157955A0 IL 157955 A0 IL157955 A0 IL 157955A0 IL 15795502 A IL15795502 A IL 15795502A IL 15795502 A IL15795502 A IL 15795502A IL 157955 A0 IL157955 A0 IL 157955A0
Authority
IL
Israel
Prior art keywords
drug
alpha
methylpropiono
fluorophenylsulphonyl
toluidide
Prior art date
Application number
IL15795502A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL157955(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0101171A external-priority patent/SE0101171D0/xx
Priority claimed from SE0102957A external-priority patent/SE0102957D0/xx
Priority claimed from SE0103565A external-priority patent/SE0103565D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL157955A0 publication Critical patent/IL157955A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15795502A 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp IL157955A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0101171A SE0101171D0 (sv) 2001-04-02 2001-04-02 Pharmaceutical formulation
SE0102957A SE0102957D0 (sv) 2001-09-04 2001-09-04 Pharmaceutical formulation
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation
PCT/GB2002/001439 WO2002080902A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Publications (1)

Publication Number Publication Date
IL157955A0 true IL157955A0 (en) 2004-03-28

Family

ID=27354679

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15795502A IL157955A0 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp

Country Status (21)

Country Link
US (1) US20040138299A1 (xx)
EP (1) EP1381358B1 (xx)
JP (1) JP2004525164A (xx)
KR (1) KR20030087048A (xx)
CN (1) CN1536993A (xx)
AT (1) ATE324886T1 (xx)
BR (1) BR0208421A (xx)
CA (1) CA2443040A1 (xx)
CZ (1) CZ20032647A3 (xx)
DE (1) DE60211139T2 (xx)
EE (1) EE200300476A (xx)
ES (1) ES2261655T3 (xx)
HU (1) HUP0303454A3 (xx)
IL (1) IL157955A0 (xx)
IS (1) IS6970A (xx)
MX (1) MXPA03008999A (xx)
NO (1) NO20034386L (xx)
NZ (1) NZ528284A (xx)
PL (1) PL365330A1 (xx)
SK (1) SK12032003A3 (xx)
WO (1) WO2002080902A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60206889T2 (de) * 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
BR112013013028B1 (pt) 2011-01-13 2021-02-09 Bio-Pharm Solutions Co., Ltd processo para a preparação de derivados de carbamato de fenila e composto
CN104136413B (zh) 2011-12-27 2016-10-26 比皮艾思药物研发有限公司 用于预防或治疗癫痫症的苯基氨基甲酸酯化合物
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
EP3016641B1 (de) 2013-07-03 2018-09-05 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit elektronischem bauteil
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
EP3145502B1 (en) * 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
EP4238580A3 (en) 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
AU2015358493B2 (en) 2014-12-05 2021-05-06 Aragon Pharmaceuticals, Inc. Anticancer compositions
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
CN1536993A (zh) 2004-10-13
US20040138299A1 (en) 2004-07-15
HUP0303454A2 (hu) 2004-01-28
NZ528284A (en) 2005-04-29
PL365330A1 (en) 2004-12-27
JP2004525164A (ja) 2004-08-19
CA2443040A1 (en) 2002-10-17
EE200300476A (et) 2003-12-15
BR0208421A (pt) 2004-03-30
DE60211139T2 (de) 2007-03-01
EP1381358B1 (en) 2006-05-03
NO20034386L (no) 2003-11-28
NO20034386D0 (no) 2003-10-01
HUP0303454A3 (en) 2005-12-28
DE60211139D1 (de) 2006-06-08
IS6970A (is) 2003-09-29
WO2002080902A1 (en) 2002-10-17
CZ20032647A3 (cs) 2004-09-15
SK12032003A3 (sk) 2004-03-02
ATE324886T1 (de) 2006-06-15
MXPA03008999A (es) 2004-02-12
ES2261655T3 (es) 2006-11-16
EP1381358A1 (en) 2004-01-21
KR20030087048A (ko) 2003-11-12

Similar Documents

Publication Publication Date Title
IL157955A0 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
WO2002067893A3 (en) Pharmaceutical formulation comprising bicalutamide
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
IL174561A0 (en) Drug coating providing high drug loading and methods for providing the same
DE60217367D1 (de) Nanopartikelzusammensetzungen enthaltend insulin
DK1471892T3 (da) Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
TW200510392A (en) Chemical compounds
MXPA04003520A (es) Formulacion farmaceutica que comprende (r)-bicalutamida.
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
SE0103839D0 (sv) Pharmaceutical formulation & product
WO2002028424A3 (en) Kyberdrug as autovaccines with immune-regulating effects
SE0103838D0 (sv) Pharmaceutical formulation & product
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
CA2329665A1 (en) Treatment of depression and pharmaceutical preparations therefor
RU2003132064A (ru) Твердая фармацевтическая композиция, содержащая 4-циано-трифтор-3-(4-фторфенилсуфонил)-2-гидрокси-2-метилпропионо-м толуидид и pvp